Clinical management of venetoclax in multiple myeloma

Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the use and side effects of venetoclax for multiple myeloma (MM) in clinical practice. Venetoclax is very potent in chronic lymphocytic leukemia (CLL) and Prof Boise describes how patients treated with the drug had to stay in hospital due the associated toxicity. Multiple myeloma patients are also initially treated in hospital during the first cycle but are then able to go home. According to Prof Boise, venetoclax is fairly well tolerated and has also been tested in combination with bortezomib and dexamethasone.
Recorded at the Myeloma 2016 meeting held in Boston, MA.

Share this video